## **Table of Contents**

## State/Territory Name: Pennsylvania

### State Plan Amendment (SPA) #: PA-14-024

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS Pharmacy Team Approval Letter
- 3) CMS Form 179/Summary Form (with 179-like data)
- 4) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 150 S. Independence Mall West Suite 216, The Public Ledger Building Philadelphia, Pennsylvania 19106-3499



#### Region III/Division of Medicaid and Children's Health Operations

SWIFT # 060620144060

JUL 17 2014

Beverly Mackereth Secretary of Public Welfare Department of Public Welfare Room 333, Health & Welfare Building P.O. Box 2675 Harrisburg, Pennsylvania 17105-2675

Dear Ms. Mackereth:

The Centers for Medicare & Medicaid Services (CMS) has completed its review of Pennsylvania's State Plan Amendment (SPA) PA-14-024. We are pleased to inform you that SPA PA-14-024 has been approved.

SPA PA-14-024 proposed to add Immune Globulins to the list of drugs that require prior authorization. This amendment reflects changes in the prior authorization policy for pharmacy services.

The effective date of this amendment is June 2, 2014. This SPA was approved by the CMS Pharmacy Team on July 8, 2014. You should have received a letter from Larry Reed, Director of the Division of Pharmacy.

Enclosed, please find the signed CMS 179 form, and the approved SPA pages.

If you have any questions concerning this letter, please contact Mary McKeon at (215) 861-4181.

Sincerely.

1-

1

Trancis Niccunougn Associate Regional Administrator

Enclosures

cc: Daniel Sorge, DPW, Bureau of Policy, Analysis and Planning Terry Simananda, Division of Pharmacy, CMCS DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



#### **Disabled & Elderly Health Programs Group**

July 8, 2014

Ms. Beverly Mackereth Secretary of Public Welfare Commonwealth of Pennsylvania Department of Public Welfare Office of Medical Assistance Programs Bureau of Policy, Analysis and Planning Health & Welfare Building P.O. Box 8046 Harrisburg, PA 17105-2675

Dear Ms. Mackereth:

We have reviewed Pennsylvania State Plan Amendment (SPA) 14-024, Prescribed Drugs – Limitations on Payment, received in the Regional Office on June 5, 2014. This amendment proposed to add Immune Globulins to the list of drugs that require prior authorization.

We are pleased to inform you that the amendment is approved, effective June 2, 2014. A copy of the CMS-179 form, as well as the pages approved for incorporation into the Pennsylvania state plan, will be forwarded by the Philadelphia Regional Office. If you have any questions regarding this amendment, please contact Terry Simananda at (410) 786-8144.

Sincerely,

/s/

Joseph L. Fine Acting Director Division of Pharmacy

cc: Francis McCullough, ARA, Philadelphia Regional Office Mary McKeon, Philadelphia Regional Office

EPARTMENT OF HEALTH AND HUMAN SERVICES EALTH CARE FINANCING ADMINISTRATION		FORM APPROVED OMB NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER: 14-024	2. STATE Pennsylvania
FOR: HEALTH CARE FINANCING ADMINISTRATION	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)	
TO: REGIONAL ADMINISTRATOR HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE June 2, 2014	
5. TYPE OF PLAN MATERIAL (Check One):		a de anti-
	CONSIDERED AS NEW PLAN	AMENDMENT
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME		h amendment)
6. FEDERAL STATUTE/REGULATION CITATION: Section 1927 of the Social Security Act	7. FEDERAL BUDGET IMPACT: a. FFY 2014 \$0.00 b. FFY 2015 \$0.00	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable):	
Page 5eb of Attachment 3.1.A	Page 5eb of Attachment 3.1.A	*
<ul> <li>I1. GOVERNOR'S REVIEW (Check One):</li> <li>GOVERNOR'S OFFICE REPORTED NO COMMENT</li> <li>COMMENTS OF GOVERNOR'S OFFICE ENCLOSED</li> <li>NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL</li> </ul>		CIFIED: Review and y has been delegated t of Public Welfare
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO: Commonwealth of Pennsylvania	
/S/	<ul> <li>Department of Public Welfare</li> </ul>	
Beverly D. Mackereth	Office of Medical Assistance Prog Bureau of Policy, Analysis and Pla	
14. TITLE: Secretary of Public Welfare	P.O. Box 8046	uuung
5 DATE SUBMITTED	- Harrisburg, Pa.17105	
JUN - 4 2014		
FOR REGIONAL OF		
17. DATE RECEIVED: JUN 0 4 2014	18. DATE APPROVED: JUL 0	8/2014
PLAN APPROVED – ON 19. EFFECTIVE DATE OF APPROVED MATERIAL:		ECIAL:
	20 SIGHT URE OF REGIONARD	ECIAL:

# STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT STATE: COMMONWEALTH OF PENNSYLVANIA DESCRIPTION OF LIMITATIONS

## ATTACHMENT 3.1A Page 5eb

	SERVICE		LIMITATIONS	
2.	Prescribed Drugs, Dentures, and Prosthetic Devices, and Eyeglasses			
12.a.	Prescribed Drugs Limitations (continued)		Payment	
	(continued)	3.	Drugs not included on the Preferred Drug List, and designated as non-preferred	
		4.	Reserved	
		5.	Reserved	
		6.	Synagis	
		7.	Xolair	
		· 8.	Tysabri	
		9. disper quant 10.	Early Refills – a request for a refill when more than 15 percent of an earlier- nsed medication would remain when taken in compliance with the directions and ity prescribed. Reserved	
		11.	Legend and non-legend cough and cold medications when prescribed for	
			en under 6 (six) years of age.	
		12.	Reserved	
		13.	Reserved	
		14.	Benzodiazepines when prescribed for children under age 21 or that represents	
			cate therapy.	
		15.	Reserved	
		16.	Nuedexta	
		17.	Makena	
		18.	Xyrem	
		19.	Kalydeco	
		20.	Korlym H.P. Acthar Gel	
		21.	Vecamyl	
		23.	Immune Globulins	
		(f) Drug	Rebate Agreements	
		in cor Pharr confic	The Commonwealth is in compliance with section 1927 of the Social Security The state will cover drugs of federal rebate participating manufacturers. The state npliance with reporting requirements for utilization and restrictions to coverage. naceutical manufacturers can audit utilization data. The unit rebate amount is dential and cannot be disclosed for purposes other than rebate invoicing and cation.	
			The Commonwealth will be negotiating supplemental rebates in addition to the al rebates provided for in Title XIX. Rebate agreements between the Commonweal pharmaceutical manufacturer will be separate from the federal rebates.	
		Solut	CMS authorized a rebate agreement between the Commonwealth and a drug ifacturer for drugs provided to Medicaid recipients, "TOP\$ <sup>sm</sup> The Optimal PDL ion State Supplemental Rebate Agreement Among Participating Medicaid Program der Synergies, L.L.C. and (Manufacturer)".	
		additi know sepa Com be sh	The Commonwealth will continue state-specific supplemental rebates and will participate in a multi-state pooling program that will negotiate supplemental rebate on to federal rebates provided for in Title XIX. This multi-state pooling program is n as The Optimal PDL Solution (TOP\$ <sup>sm</sup> ). TOP\$ <sup>sm</sup> rebate agreements will be rate from the federal rebates. TOP\$ <sup>sm</sup> supplemental rebates received by the monwealth in excess of those required under the federal drug rebate agreement w ared with the federal government on the same percentage basis as applied under deral rebate agreement.	
		5. Optin effect	CMS has authorized the Commonwealth of Pennsylvania to enter into "The nal PDL Solution (TOP\$ <sup>sm</sup> )." The TOP\$ <sup>sm</sup> supplemental rebate agreement is tive October 1, 2013 for the Commonwealth of Pennsylvania.	